Working... Menu
Trial record 1 of 6 for:    hymovis
Previous Study | Return to List | Next Study

Hymovis™ Versus Placebo in Knee Osteoarthritis (Hymovis)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01372475
Recruitment Status : Completed
First Posted : June 14, 2011
Last Update Posted : April 8, 2014
Information provided by (Responsible Party):
Fidia Farmaceutici s.p.a.

Brief Summary:
Purpose: The purpose of this study is to demonstrate if the intra-articular injection of a new viscoelastic Hydrogel (Hymovis) is superior to Placebo (phosphate buffered saline [PBS] in subjects with symptomatic osteoarthritis of the knee.

Condition or disease Intervention/treatment Phase
Knee Osteoarthritis Device: Hymovis Intra-articular Injection Procedure: Phosphate Buffered Saline Injection Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 800 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multi-Centre, Double-Blind, Randomized, Placebo Controlled Study To Evaluate The Safety And Effectiveness Of A New Viscoelastic Hydrogel (Hymovis) In The Treatment Of Knee OA With An Open-Label Extension
Study Start Date : March 2011
Actual Primary Completion Date : November 2012
Actual Study Completion Date : February 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis

Arm Intervention/treatment
Active Comparator: Hymovis Viscoelastic Hydrogel
Intra-articular Injection
Device: Hymovis Intra-articular Injection
Hymovis Intra-articular injection
Other Names:
  • HYADD4™
  • Hyaluronic Acid
  • HA
  • Hyaluronate

Placebo Comparator: Placebo
Phosphate Buffered Saline Intra-articular Injection
Procedure: Phosphate Buffered Saline Injection
Placebo Intra-articular injection
Other Names:
  • PBS
  • Saline

Primary Outcome Measures :
  1. Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Pain sub-score [ Time Frame: 26 weeks ]
    WOMAC A Pain sub-score

Secondary Outcome Measures :
  1. Responder Analysis [ Time Frame: 26 weeks ]
    Outcome Measures in Rheumatoid Arthritis Clinical Trials - Osteoarthritis Research Society International (OMERACT-OARSI) Criteria

  2. WOMAC Function [ Time Frame: 26 Weeks ]
    WOMAC C Function sub-score

  3. Visual Analog Scale (VAS) WOMAC Pain [ Time Frame: 26 Weeks ]
    Question A1 of WOMAC Pain sub-score

  4. WOMAC Global Score [ Time Frame: 26 Weeks ]
  5. WOMAC Stiffness sub-score [ Time Frame: 26 Weeks ]
    WOMAC C stiffness sub-score

  6. Rescue Medication Usage Pill Count, Failure Outcome [ Time Frame: 26 Weeks ]
  7. Patient Global Analysis [ Time Frame: 26 Weeks ]
  8. Clinician Responder Analysis [ Time Frame: 26 Weeks ]
  9. SF Health Outcome [ Time Frame: 26 Weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female ambulant outpatients ≥ 40 years of age with an active lifestyle:
  2. Has a medical history of OA symptoms confirmed at least 3 months prior to the screening visit with radiographic evidence of OA, Kellgren-Lawrence grade 2-3
  3. Discontinuation of any analgesic/NSAID therapy prior to baseline with no intent to resume during study

Exclusion Criteria:

  1. Clinically significant apparent large effusion of the target knee;
  2. Clinically significant valgus/varus deformities, ligamentous laxity or meniscal instability as assessed by the Investigator;
  3. Any musculoskeletal condition affecting the target knee that would impair assessment of the effectiveness in the target knee such as Paget's disease
  4. Medical history of anaphylactic reactions
  5. History of septic arthritis in any joint
  6. Females who are pregnant or breast-feeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01372475

  Show 33 Study Locations
Sponsors and Collaborators
Fidia Farmaceutici s.p.a.
Layout table for investigator information
Study Director: Cynthia Secchieri, PhD Fidia Farmceutici S.p.A.

Layout table for additonal information
Responsible Party: Fidia Farmaceutici s.p.a. Identifier: NCT01372475     History of Changes
Other Study ID Numbers: R29-09-02
First Posted: June 14, 2011    Key Record Dates
Last Update Posted: April 8, 2014
Last Verified: March 2014

Keywords provided by Fidia Farmaceutici s.p.a.:
Hyaluronic Acid

Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoarthritis, Knee
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Hyaluronic Acid
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Protective Agents